Protocols

The available evidence provides limited specific dosing protocol information for exenatide. Based on the clinical trials and research identified:

Immediate-Release Formulation

Clinical trials have investigated exenatide as an add-on therapy to existing diabetes treatments, though specific dosing details are not provided in the available abstracts. The DURATION-1 trial examined exenatide long-acting release formulations for glucose control in type 2 diabetes.

Long-Acting Formulation

The DURATION-1 phase 3 trial studied exenatide long-acting release (LAR) for glucose control and safety in type 2 diabetes patients, indicating this formulation has been evaluated in controlled clinical settings.

Investigational Formulations

Early-phase research is exploring novel delivery methods, including:

Exenatide circular RNA-lipid nanoparticle injection (CR059) currently in phase 1 testing
Bioinspired nanoarchitectures using stimuli-responsive materials for peptide delivery

Alternative Applications

Beyond diabetes management, studies have examined exenatide's use as a diagnostic test for endogenous hyperinsulinemic hypoglycemia, suggesting protocols may vary based on clinical indication.

Evidence Limitations

The current evidence base does not provide detailed dosing schedules, titration protocols, or administration timing from the available study abstracts. More comprehensive protocol information would require access to full study methodologies and prescribing guidelines.

Disclaimer: This information is for educational purposes only and should not be considered personalized medical advice. Dosing protocols must be determined by qualified healthcare providers based on individual patient factors, current prescribing guidelines, and clinical judgment.

Exenatide

Member access required